Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Etigilimab |
| Trade Name | |
| Synonyms | OMP313M32|OMP 313M32|OMP-313M32|WHO 10742|MPH313 |
| Drug Descriptions |
Etigilimab (OMP-313M32) is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (AACR, Vol 58, April 2017, Abstract #599, PMID: 31874056). |
| DrugClasses | Immune Checkpoint Inhibitor 150 TIGIT Antibody 20 |
| CAS Registry Number | 2044984-83-8 |
| NCIT ID | C142821 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Etigilimab | Etigilimab | 0 | 1 |
| Etigilimab + Nivolumab | Etigilimab Nivolumab | 0 | 2 |